Oculis names Sharon Klier as chief development officer

Swiss ophthalmology specialist Oculis Holding (Nasdaq: OCS) has appointed Dr Sharon Klier to the role of chief development officer (CDO).

In this key role, Dr Klier, an executive leader with extensive experience in clinical development across early and late-stage programs, regulatory submissions, and approvals, will oversee and provide strategic leadership across the clinical development and operations of Oculis’ robust ophthalmology pipeline.

Dr Klier has over 20 years’ experience developing and executing global clinical development strategies that have supported product approvals and successful launches in retina and corneal diseases. Before joining Oculis, she served as CDO, head of ophthalmology at UNITY Biotechnology, where she played a key role in driving forward UNITY’s pipeline. Prior to that, Dr Klier held roles of increasing responsibility at several companies including Quark, Allergan, ISTA and Pfizer (NYSE: PFE), where she gained extensive experience in ophthalmology, particularly in retinal diseases, neuro-ophthalmology, and ocular inflammation.